

CO-OPTION OF A NEW DIRECTOR TO REPLACE A RESIGNING MEMBER OF THE BOARD

SHAREHOLDERS' MEETING CONVENED ON 29 APRIL 2025

Trento, 12 March 2025

GPI S.p.A. (GPI:IM), a leading company in the digital transformation of Healthcare, listed on the Euronext Milan Tech Leaders market, today announces that Executive Director Sergio Manzana has resigned from his position as Director and member of the Strategic Committee, due - among other things - to his recent professional commitment as Chairman of the French Joint Venture The Drug Cell, constituted by GPI France and eight other leading French entities in the biotechnology and innovation sector. The Drug Cell, also the recipient of €152 million in funding from France's General Secretariat for Investment, aims to become a benchmark in France and Europe for regenerative medicine and a pioneer in the industrialisation of advanced cell therapies.

The Company extends sincere thanks to the outgoing Director for the appreciated contribution and for the professionalism demonstrated during the board term.

At the time of his resignation, Sergio Manzana did not hold any shares in the Company. It should also be noted that no remuneration or entitlement is payable in connection with the termination of office.

The Board of Directors resolved to appoint Andrea Di Santo as *(i)* Director of the Company, by co-option, pursuant to Article 13 of the Company's Articles of Association and Article 2386 of the Italian Civil Code, as well as *(ii)* member of the Strategic Committee, which is now composed of the following members: Luca d'Agnese (President), Fausto Manzana, Andrea Di Santo and Mario Vitale.

Andrea di Santo will remain in office until the next Shareholders' Meeting.

At today's meeting, the Board of Directors also verified that Andrea Di Santo met the requirements of honourableness and eligibility set forth by current legislation and the Corporate Governance Code, the existence of which was certified by the newly elected Director.

The curriculum vitae of Director Andrea Di Santo is available on the Company's website at <http://www.gpigroup.com/en/investors/governance/> - Board of Directors.

* . * . *

We also inform you that the Board of Directors, which met today, resolved to convene the Ordinary Shareholders' Meeting on 29 April 2025 in a single call.

Shareholders are convened to deliberate on the 2024 Financial Statements and the allocation of profits, on Section II of the "Report on the remuneration policy and compensation paid in the 2024 financial year", on the proposal to integrate the Board of Directors – due to the expiry of the mandate of the newly co-opted

Director at the next Shareholders' Meeting –, on the appointment of the Board of Statutory Auditors and on the determination of the related compensation as well as on the authorization to purchase and dispose of treasury shares, subject to revocation of the resolution adopted by the Shareholders' Meeting of 29 April 2024 for any unused portion.

The documents relating to the Shareholders' Meeting will be made available to the public in accordance with the law and regulations.

GPI GROUP

Gpi's mission is to make the healthcare systems sustainable through their digitisation, so that everyone can receive high-quality care. **Sustainability and social impact** are the guiding principles and play a crucial role in the strategic and investment assessments of the Group, aware that the solutions and services provided to the community have an impact on the quality of life of individuals.

For 35 years, driven by a patient-centric vision, Gpi has been working to support healthcare systems by providing the skills and innovative tools necessary to improve prevention and treatment processes. This is achieved through the strategic use of advanced software, technologies, and cutting-edge services.

The Group's strategy is designed to meet the evolving requirements of the constantly changing healthcare sector and to facilitate entry into international markets.

The unwavering commitment of its 7,600 employees and a customer base of more than 9,000 across 70 countries, yielded €433 million in revenue, an EBITDA of €80 million in 2023.

Gpi S.p.A. is listed on the Euronext Tech Leaders segment of Borsa Italiana, the Italian stock exchange.

ISIN ordinary shares: IT0005221517

This press release is also available at www.gpigroup.com and www.1info.it

CONTACTS

Investor Relations

GPI | Fabrizio Redavid, Lorenzo Giollo | investor.relations@gpi.it | T: +390461381515 | Via Ragazzi del '99, 13 - 38123 Trento

Media Relations

GPI | Daniela Filbier, Enrico Orfano | media.relations@gpi.it | T: +390461381515 | Via Ragazzi del '99, 13 - 38123 Trento

Specialist

Banca Akros | Bruno Mestice | bruno.mestice@bancaakros.it | T: +3902434441 | Viale Eginardo, 29 – 20149 Milan